SCHEMBL263139

SCHEMBL263139

Cn1nccc1C(=O)Nc1ccc(-c2cc(F)ccc2OC2CC2)c(N)n1

nearest known ligand 0.68

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
SCN10A Q9Y5Y9 10/20 0.68
SCN5A Q14524 2/20 0.55
SCN9A Q15858 2/20 0.55
SCN1A P35498 1/20 0.55
CDK2 P24941 4/20 0.40
HTT P42858 1/20 0.39
CCNE1 P24864 3/20 0.39
GSK3B P49841 3/20 0.39
SCN2A Q99250 1/20 0.39
SCN3A Q9NY46 1/20 0.39
MAP4K1 Q92918 1/20 0.38
RAB9A P51151 2/20 0.38
NPC1 O15118 1/20 0.38
CYP1A2 P05177 1/20 0.38
CYP2D6 P10635 1/20 0.38
CYP2C19 P33261 1/20 0.38
GALR3 O60755 1/20 0.37
TNF P01375 1/20 0.37
NOD1 Q9Y239 1/20 0.37
LMNA P02545 1/20 0.37

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL14237625 0.92 SCN10A (0.62) SCN10ASCN5ASCN9ASCN1AHTT
SCHEMBL14237518 0.87 SCN10A (0.70) SCN10ASCN5ASCN9ASCN1ASCN2A
SCHEMBL262209 0.85 SCN10A (0.70) SCN10ASCN5ASCN9ASCN1AHTT
SCHEMBL264424 0.85 SCN10A (0.81) SCN10ASCN5ASCN9ASCN1AHTT
SCHEMBL14237406 0.84 SCN10A (0.68) SCN10ASCN5ASCN9ASCN1AHTT
SCHEMBL263007 0.83 SCN10A (0.67) SCN10ASCN5ASCN9ASCN1ASCN2A
SCHEMBL14237480 0.83 SCN10A (0.67) SCN10ASCN5ASCN9ASCN1ASCN2A
SCHEMBL263433 0.82 SCN10A (0.86) SCN10ASCN5ASCN9ASCN1AHTT
SCHEMBL262879 0.81 SCN10A (0.60) SCN10ASCN5ASCN9ASCN2ASCN3A
SCHEMBL14237713 0.81 SCN10A (0.64) SCN10ASCN5ASCN9ASCN1AHTT

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 8 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
EP-2183241-B1 2-PYRIDINE CARBOXAMIDE DERIVATIVES AS SODIUM CHANNEL MODULATORS PFIZER LTD (GB) 2012-12-19 EP claimed
US-8134007-B2 Pyridine derivatives PFIZER INC. (US) 2012-03-13 US claimed
JP-4657384-B2 2011-03-23 JP claimed
JP-2010526050-A 2010-07-29 JP claimed
EP-2183241-A2 2-PYRIDINE CARBOXAMIDE DERIVATIVES AS SODIUM CHANNEL MODULATORS Pfizer Limited (GB) 2010-05-12 EP claimed
US-20090048306-A1 PYRIDINE DERIVATIVES PFIZER, INC. (US) 2009-02-19 US claimed
WO-2008135826-A2 2 -PYRIDINE CARBOXAMIDE DERIVATIVES AS SODIUM CHANNEL MODULATORS PFIZER LIMITED (GB) 2008-11-13 WO claimed
EP-2183241-B1 2-PYRIDINE CARBOXAMIDE DERIVATIVES AS SODIUM CHANNEL MODULATORS PFIZER LTD (GB) 2012-12-19 EP disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20090048306-A1 PYRIDINE DERIVATIVES SDHA, P2RX4, P2RX3 SCN10A 358/4885SCN5A 157/4885SCN9A 491/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.